In ER+ breast cancers, CD146 distinguishes two CAF subgroups: CD146+ CAFs maintain ER expression, estrogen-dependent proliferation, and sensitivity to tamoxifen, whereas CD146− CAFs play the opposite role [207]. Here, ESR1 is linked to breast cancer.